INTRODUCTION AND OBJECTIVES: Postoperative perinephric fluid collections are common after pediatric renal transplantation (RT), and may be caused by clinical entities such as urinoma, hematoma, and lymphocele. These collections are usually monitored with serial ultrasounds. Size, etiology, extrinsic ureteral obstruction and/or the presence of symptoms dictate management. We hypothesized that these fluid collections rarely require intervention, and gain little benefit from close follow-up with imaging in the presence of stable clinical status (asymptomatic with stable renal function) and absence of hydronephrosis.
INTRODUCTION AND OBJECTIVES: Postoperative perinephric fluid collections are common after pediatric renal transplantation (RT), and may be caused by clinical entities such as urinoma, hematoma, and lymphocele. These collections are usually monitored with serial ultrasounds. Size, etiology, extrinsic ureteral obstruction and/or the presence of symptoms dictate management. We hypothesized that these fluid collections rarely require intervention, and gain little benefit from close follow-up with imaging in the presence of stable clinical status (asymptomatic with stable renal function) and absence of hydronephrosis.
METHODS: Retrospective review was performed of all children who underwent pediatric RT at our institution within the last five years (2010) (2011) (2012) (2013) (2014) and monitored at least 1 month postoperatively. Perinephric fluid collections on postoperative renal ultrasounds were measured in 3 axes and correlated with clinical parameters and symptomatology. Indicated interventions including image-guided drainage and surgery were captured.
RESULTS: 103 children underwent RT (59 deceased and 44 living-related donor) over this period, at a mean age of 10.6AE5.4 years. Only 37 patients (36%) had no peri-nephric collections on ultrasound at two weeks postoperatively. Sixty-six patients (64%) had fluid collections, 14 of which underwent intervention: 9 lymphoceles (8.7%), 3 infected hematomas (2.9%), and 2 urinomas (1.9%). Four patients with lymphoceles underwent laparoscopic marsupialization after failed drainage and/or sclerotherapy. The average fluid collection volume was 169 cm 3 ; 618 cm 3 in the intervention group compared to 46 cm 3 in those observed.
CONCLUSIONS: Peri-nephric fluid collections are common after pediatric renal transplantation, the majority of which do not require intervention. Larger volume fluid collections were associated with intervention and are usually secondary to lymphoceles.
Source of Funding: None.
MP74-11 ADVERSE EVENTS IN THERAPEUTIC PLASMA EXCHANGE USING FRESH-FROZEN PLASMA IN KIDNEY TRANSPLANT RECIPIENTS
Mitsuru Saito*, Takamitsu Inoue, Shintaro Narita, Atsushi Maeno, Hiroshi Tsuruta, Kazuyuki Numakura, Shigeru Satoh, Tomonori Habuchi, Akita, Japan INTRODUCTION AND OBJECTIVES: For successful kidney transplantation, patients who are at immunological high risk, such as those who have an ABO blood type incompatibility with the donor and/or who are positive for donor specific anti-HLA antibodies, should undergo apheresis therapy. For apheresis therapy, immunoadsorption, double filtration plasmapheresis (DFPP), or plasma exchange is often performed. Plasma exchange using fresh-frozen plasma (FFP) often causes unpleasant adverse events. However, there are few reports on the incidence and profile of adverse events during therapeutic plasma exchange in kidney transplant recipients.
METHODS: From April 2005, 53 kidney transplant recipients (including 6 preemptive cases) at immunological high risk were enrolled in this study. For desensitization, they underwent three or four sessions of apheresis therapy (two or three sessions of DFPP and one or two sessions of plasma exchange). They also received a single dose of rituximab at 200 mg/body 3 weeks before transplantation. The induction immunosuppressive therapy consisted of tacrolimus, mycophenolate mofetil, steroid, and basiliximab. All patients with antibody-mediated rejection (ABMR) received apheresis therapy (plasma exchange or DFPP), steroid pulse therapy, and administration of low-dose (100 mg/ kg) immunoglobulin intravenously for 3 to 5 days. Three liters of FFP equivalent to the total plasma volume in each patient was used during each session of plasma exchange. We evaluated adverse events during 88 sessions of plasma exchange (62 sessions, including 12 sessions combined with hemodialysis preoperatively, and 26 sessions for ABMR). Adverse events were evaluated by the Common Terminology Criteria for Adverse Events Version 4.0.
RESULTS: The incidence of adverse events was 83% (73/88). The principal events were pruritus 53% (47/88), numbness (hypocalcemic symptoms) 40% (35/88), urticaria 33% (29/88), chill 19% (17/88), nausea and vomiting 13% (11/88), mild dyspnea 5% (4/88), and mild hypotension 3% (3/88). Severe adverse events (grade 3 or over) were not recorded. The incidence of adverse events was significantly higher at pretransplantation than at posttransplantation (p < 0.001). No differences were found in the incidence of adverse events between preemptive cases and patients receiving maintenance dialysis. The incidence of numbness during plasma exchange was significantly less (p ¼ 0.009) in patients receiving combined hemodialysis than in those not receiving hemodialysis.
CONCLUSIONS: During therapeutic plasma exchange using FFP in kidney transplant recipients, pruritus, numbness, and urticaria commonly occur. In patients with chronic renal failure, plasma exchange combined hemodialysis may be useful to prevent numbness. The incidence and severity of adverse events during plasma exchange may be associated with kidney function. is a causative agent of BKV-associated nephropathy (BKVN) and hemorrhagic cystitis, which occur subsequent to the reactivation of BKV. Although the clinical implications of antibodies against BKV have not yet been clarified, intravenous immunoglobulin (IVIg), which is presumed to have significant neutralizing activity, may represent a promising approach for the control of BKV-associated diseases. The objective of this study was to measure anti-BKV antibody titer in an IVIg preparation as well as in renal transplant recipients and to examine its significance as a clinical marker.
Source of Funding: None
METHODS: Three IVIg products derived from donated blood samples in Japan as well as clinical samples from 45 recipients of kidney transplants at Akita University Hospital were used for evaluation of neutralizing titers and antibody titers. A reliable method of measurement using the human lung (carcinoma) cell line A549 and the Gardner strain of BKV was established to quantitatively determine neutralizing activity. Antibody titers in the samples were evaluated by neutralizing capacity and binding capacity, using enzyme-linked immunosorbent assays.
RESULTS: The mean neutralizing titer against BKV was 2,687-fold (AE558) higher in pooled plasma and 12,014-fold (AE2,145) higher in IVIg products concentrated from pooled plasma. Stable high antibody titers of all IVIgs were found against BKV subtype I/c, which Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e999
